Replimune Group Inc [REPL] stock is trading at $8.35, down -4.68%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The REPL shares have gain 6.37% over the last week, with a monthly amount drifted -7.84%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Replimune Group Inc [NASDAQ: REPL] stock has seen the most recent analyst activity on August 28, 2024, when ROTH MKM initiated its Buy rating and assigned the stock a price target of $17. On November 19, 2021, Piper Sandler initiated with a Overweight rating and assigned a price target of $52 on the stock. BTIG Research initiated its recommendation with a Buy and recommended $60 as its price target on November 17, 2020. Jefferies started tracking with a Buy rating for this stock on November 02, 2020, and assigned it a price target of $67. In a note dated October 15, 2020, H.C. Wainwright upgraded an Buy rating on this stock and boosted its target price from $25 to $54.
Replimune Group Inc [REPL] stock has fluctuated between $4.92 and $17.00 over the past year. Currently, Wall Street analysts expect the stock to reach $23 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $8.35 at the most recent close of the market. An investor can expect a potential return of 175.45% based on the average REPL price forecast.
Analyzing the REPL fundamentals
Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -59.64%, Pretax Profit Margin comes in at -56.34%, and Net Profit Margin reading is -56.47%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -0.54 and Total Capital is -0.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.86 points at the first support level, and at 7.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.79, and for the 2nd resistance point, it is at 9.23.
Ratios To Look Out For
For context, Replimune Group Inc’s Current Ratio is 7.95. As well, the Quick Ratio is 7.95.
Transactions by insiders
Recent insider trading involved Astley-Sparke Philip, Director, that happened on May 20 ’25 when 32279.0 shares were sold. Chief Medical Officer, Xynos Konstantinos completed a deal on May 20 ’25 to sell 7952.0 shares. Meanwhile, Chief Accounting Officer Schwendenman Andrew sold 3287.0 shares on May 20 ’25.
